Covid-19: Moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy
- PMID: 33268462
- DOI: 10.1136/bmj.m4709
Covid-19: Moderna applies for US and EU approval as vaccine trial reports 94.1% efficacy
Similar articles
-
"COVID arm": A reaction to the Moderna vaccine.JAAD Case Rep. 2021 Apr;10:92-95. doi: 10.1016/j.jdcr.2021.02.014. Epub 2021 Feb 25. JAAD Case Rep. 2021. PMID: 33748377 Free PMC article. No abstract available.
-
Covid-19: UK approves Moderna vaccine to be given as two doses 28 days apart.BMJ. 2021 Jan 11;372:n74. doi: 10.1136/bmj.n74. BMJ. 2021. PMID: 33431500 No abstract available.
-
National Differences in Requirements for Ethical and Competent Authority Approval for a Multinational Vaccine Trial under the EU Directive 2001/20/EC.Vaccines (Basel). 2015 Apr 14;3(2):263-92. doi: 10.3390/vaccines3020263. Vaccines (Basel). 2015. PMID: 26343188 Free PMC article. Review.
-
Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.J Clin Pharm Ther. 2010 Jun;35(3):289-301. doi: 10.1111/j.1365-2710.2009.01099.x. J Clin Pharm Ther. 2010. PMID: 20848767
-
Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine.Drugs R D. 2008;9(2):131-5. doi: 10.2165/00126839-200809020-00007. Drugs R D. 2008. PMID: 18298131 Review.
Cited by
-
COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.Biomed Res Int. 2023 Aug 29;2023:1879554. doi: 10.1155/2023/1879554. eCollection 2023. Biomed Res Int. 2023. PMID: 37674935 Free PMC article. Review.
-
A comprehensive insight on the challenges for COVID-19 vaccine: A lesson learnt from other viral vaccines.Heliyon. 2023 Jun;9(6):e16813. doi: 10.1016/j.heliyon.2023.e16813. Epub 2023 Jun 7. Heliyon. 2023. PMID: 37303517 Free PMC article. Review.
-
Efficient CRISPR-Cas13d-Based Antiviral Strategy to Combat SARS-CoV-2.Viruses. 2023 Mar 6;15(3):686. doi: 10.3390/v15030686. Viruses. 2023. PMID: 36992394 Free PMC article.
-
Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study.Vaccines (Basel). 2023 Mar 1;11(3):566. doi: 10.3390/vaccines11030566. Vaccines (Basel). 2023. PMID: 36992150 Free PMC article.
-
An overview on the treatments and prevention against COVID-19.Virol J. 2023 Feb 8;20(1):23. doi: 10.1186/s12985-023-01973-9. Virol J. 2023. PMID: 36755327 Free PMC article. Review.
LinkOut - more resources
Full Text Sources